Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. AstraZeneca and Ionis add an EU green light to ...
MarketBeat on MSN24y
bluebird bio: How to play LEAPS options for growth and incomeGene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG (NASDAQ: ...
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...
Hosted on MSN11mon
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's WhyCrispr stock is tumbling for the fifth straight week as the top Cathie Wood's holding struggles amid dimming expectations for its new Vertex-partnered gene-editing drug. Please watch the video at ...
Casgevy faces competition from BlueBird Bio’s Lyfgenia, priced at $3.1 million, 40% higher than Casgevy’s $2.2 million. Lyfgenia also carries a black box warning for blood cancer risk ...
The FDA approved Lyfgenia and Vertex Pharmaceuticals' (VRTX) Casgevy for the treatment of sickle cell disease in December 2023. Casgevy was co-developed with CRISPR Therapeutics (CRSP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback